(Stroke. 2001;32:6.)
© 2001 American Heart Association, Inc.
An Animal Model for the Molecular Genetics of CADASIL
Karl J. Fryxell, PhD;
Marcus Soderlund, BS
Theodor V. Jordan, MS
From the Department of Biology, George Mason University, Fairfax, Va.
Correspondence to Karl J. Fryxell, Department of Biology, MSN 3E1, George Mason University, Fairfax, VA 22030. E-mail kfryxell{at}gmu.edu
 |
Abstract
|
|---|
BackgroundCADASIL
(cerebral autosomal dominant arteriopathy
with subcortical infarcts and
leukoencephalopathy) is an inherited
condition that causes repeated
small-scale strokes in adults.
CADASIL is caused only by mutations in
the human
NOTCH3 gene
that
increase or decrease the number of cysteines within the
epidermal
growth factor (EGF) repeats of the NOTCH3 protein.
Drosophila lethal-Abruptex is a
similar condition because it is also caused
only by mutations that
increase or decrease the number of cysteines
within the EGF repeat
portion of the Notch protein.
Summary of
CommentDrosophila
lethal-Abruptex and human CADASIL are precisely analogous at the
molecular level, and both are genetically dominant. These precise
similarities, together with the fact that the structure and function of
Notch has been highly conserved throughout the animal kingdom, provide
an animal model for the molecular and genetic aspects of human CADASIL.
It also provides support for Spinners proposal that CADASIL results
from dominant inhibition of the Notch
pathway.
ConclusionsBecause the
phenotypes of Notch mutations are cell-autonomous, the symptoms
of CADASIL indicate that adult vascular smooth muscle cells require the
continuing function of the
NOTCH3 pathway in the adult.
For this reason, further analysis of the
NOTCH3 pathway may provide more
general insights into the biology of vascular smooth muscle cells. In
the case of CADASIL, the powerful genetic tools available in
Drosophila should help to
facilitate future
research.
Key Words: CADASIL dementia, multi-infarct Drosophila melanogaster genetics
 |
Introduction
|
|---|
CADASIL (cerebral
autosomal dominant arteriopathy with subcortical
infarcts and
leukoencephalopathy) causes a type of stroke and
dementia whose key
features include recurrent subcortical ischemic
events and
diffuse while matter abnormalities on
neuroimaging.
1 2 At
the behavioral level, CADASIL is associated with adult-onset
symptoms
(average age of onset is 45 years) that include migraine
headaches,
strokes, mood disorders, epileptic seizures, and
progressive
dementia.
1 3 4 5 6
CADASIL can be distinguished
from related disorders by the presence of
a family history of
autosomal dominant inheritance and skin biopsies
that show frequent
small
lesions.
7 Nevertheless,
CADASIL is currently underdiagnosed
because of its variable mode of
presentation and recent characterization.
Pathological findings on autopsy of patients with CADASIL
include multiple small, deep infarcts in the brain, a diffuse myelin
loss and pallor of the hemispheric white matter, and a widespread
vasculopathy of the small arteries penetrating the white
matter.8 The
arterial lesions occur throughout the arterial
tree, including arteries and arterioles within muscle,
skin,9 and
peripheral
nerve.10 These
arterial lesions are neither
arteriosclerotic nor
amyloid,8 11 and
affected families rarely have vascular risk factors or
hypertension.4 Nevertheless,
the arterial lesions are characterized by a marked
thickening of the arterial wall associated with the
proliferation of vascular smooth muscle cells and accumulation of extensive perivascular, eosinophilic,
osmiophilic, periodic acidSchiff positive
(PAS+) deposits in the tunica
media.8 10 11 12
Immunohistological staining patterns indicate that
these deposits may contain collagen IV and smooth muscle
myosin,11 as would be
expected after repeated cycles of smooth muscle cell degeneration and
proliferation.
The clinical severity of symptoms in CADASIL is related to
the extent of loss of white matter from the
brain,13 which occurs
progressively in CADASIL even without overt ischemic
events.2 3 Given
that white matter is particularly sensitive to partial
anoxia,13 the diffuse loss
of white matter is probably caused by widespread arteriolar
dysfunction.
 |
Both CADASIL and
Drosophila Lethal-Abruptex Are
Specifically Caused by Unpaired Cysteines Within the Epidermal Growth
Factor Repeat Domain of Notch
|
|---|
Genetic linkage
analysis
14 15
and DNA sequencing
6 have
shown
that CADASIL is caused by mutations in the human
NOTCH3 gene.
Moreover, CADASIL
mutations are invariably caused by amino acid
substitutions in the
epidermal growth factor (EGF) repeat domain
of the NOTCH3 protein that
cause the gain or loss of a
cysteine.
16 17 18
One apparent exception, a recently discovered case of
CADASIL caused by
a DNA base substitution that leads to an RNA
splicing
defect,
19 is the exception
that proves the rule, because
the aberrant RNA splicing in this case
deletes 7 amino acids
from the EGF repeat domain of the NOTCH3 protein,
and one of
the deleted amino acids is
cysteine.
19 Because all
CADASIL
mutant gene products have unpaired cysteines in the EGF
repeat
domain, the remaining cysteines may pair inappropriately or
cross-link
to other
proteins,
20 leading to
abnormal protein secondary
structure in the EGF repeat domain, which
comprises the majority
of the extracellular portion of the Notch
receptor.
21 22 23
Drosophila Abruptex
alleles are a distinct phenotypic class of mutations within the
Drosophila
Notch gene. Abruptex
alleles are classified as such, based on the presence of certain
dominant visible phenotypes such as interrupted wing veins and
a reduced number of dorsal bristles
(Figure
).24 25 26
At the molecular level, Abruptex alleles generally correspond to
amino acid substitutions within the extracellular portion of the
Drosophila Notch receptor, many
or all of which alter the binding affinity of Notch for protein ligands
such as
Delta.26 27 28

View larger version (45K):
[in this window]
[in a new window]
|
Figure 1. The Notch gene was named after mutant fruit flies with "notched wings" (left), who are typically heterozygous for a null allele (or deletion) of the Notch gene. Other mutations within this same fruit fly Notch gene cause the Abruptex phenotype, which includes interrupted wing veins and a reduced number of dorsal bristles (right). Lethal Abruptex alleles are analogous to the NOTCH3 mutations in patients with CADASIL. Redrawn after Reference 30.
|
|
Abruptex alleles have been further classified into 3
subcategories, based on classical genetic criteria: (1) viable
enhancers of Notch mutations, (2) viable suppressors of Notch
mutations, and (3) alleles that are lethal in combination with
Notch mutations (ie, lethal when heterozygous over a null allele of
Notch). On the basis of the classical genetic nomenclature of mutant
gene functions,29 these 3
subcategories of Abruptex alleles correspond to hypomorphs,
hypermorphs, and antimorphs,
respectively.24 25 26
Lethal-Abruptex alleles are said to be "antimorphs" because
they partially block the function of the normal Notch receptor in
heterozygotes. This point can be established readily in
Drosophila because of our
detailed knowledge of the phenotypic effects of various doses of genes
at each step in the Drosophila
Notch signaling
pathway.30 31 32
Drosophila lethal-Abruptex
alleles are lethal when homozygous as well as when heterozygous
over a deficiency for the Notch
gene.30
All lethal-Abruptex alleles (sequenced to date) have
amino acid substitutions that create or eliminate a cysteine within the
EGF repeat domain of the Notch receptor, whereas all hypomorphic and
hypermorphic Abruptex alleles have amino acid substitutions that
neither create nor eliminate a
cysteine.28 30
Therefore, the lethal-Abruptex phenotype is specifically caused
by unpaired cysteines in the EGF repeat domain of the Notch protein.
Unpaired cysteines presumably lead to inappropriate disulfide bonds
within the Notch receptor, abnormal secondary structure in the
extracellular domain of the Notch receptor, and perhaps cross-links to
other
proteins.20
Of course, mutations may occur in other portions of the
Drosophila Notch gene. However,
these produce phenotypes that are quite distinct from the
lethal-Abruptex phenotype. As an example, when a downstream
frameshift is added to the
Drosophila lethal-Abruptex
allele
Ax59b,
the result is a nonfunctional Notch protein that does not confer the
Abruptex
phenotype.28 A
similar situation probably exists for mammalian
NOTCH3 genes. As an example, a
mutation in the mouse Notch3
gene that does not involve cysteines produces phenotypes
(embryonic lethality) quite different from
CADASIL.33
 |
Notch Phenotypes Are
Cell-Autonomous
|
|---|
Mutations in the
Drosophila Notch gene,
including Abruptex alleles,
are expressed in a cell-autonomous
fashion.
23 31 34
In other
words, individual cells that synthesize the mutant receptor
exhibit
the mutant morphology, whereas cells that do not express the
mutant
receptor are unaffected. This aspect of Notch function has been
highly
conserved: Notch acts as a cell-autonomous receptor that
regulates
cellular proliferation, differentiation, and developmental
fate
switching in a wide variety of tissues and animal
species.
21 23
However,
Drosophila has one
Notch gene, whereas mammals
have
4
Notch genes. Each of the 4 mammalian
Notch genes acts on a
different
subset of tissues.
35 This
difference in the number
and tissue specificity of
Notch genes is presumably responsible
for the
differences in tissue specificity of Abruptex versus
CADASIL.
In the case of CADASIL, cellular defects in
arterial smooth muscle cells are caused by a
NOTCH3 mutation. This suggests
that human arterial smooth muscle cells autonomously
express the morphological consequences of the defect in their own
NOTCH3 signaling pathway. In
prenatal rodents, the normal
Notch3 gene is expressed during
gastrulation and in the developing central nervous
system.35 36 37
In postnatal rodents, Notch
gene expression is generally downregulated in most tissues. However,
the Notch3 gene of
rats38 and the
NOTCH3 gene of
humans20 continue to be
specifically expressed in adult vascular smooth muscle cells
(Table
),
whereas the NOTCH1 and
NOTCH2 genes continue to be
expressed in a few other specific
tissues.38
 |
The Structure and Molecular Functions of
Notch Have Been Highly
Conserved
|
|---|
When
Notch
genes from one animal phyla or tissue are expressed
in another animal
phyla or tissue, they have proven to be functional
in all cases so far
examined. For example, injection of mRNA
encoding activated
mouse
Notch (ie, the isolated
cytoplasmic
domain) into frog embryos produced the same effects on
embryonic
development as injection of activated frog
Notch (also known
as
Xotch).
39 40
When frog
Notch is expressed in
cultured
Drosophila cells, it
binds specifically to the correct
Drosophila ligands
(Delta and
Serrate) and even binds within the correct subdomain
of the Notch
receptor (EGF repeats 11 to 12, out of 36 EGF
repeats).
41
Evolutionary studies have shown that the arthropod and
chordate lineages diverged during the original evolutionary radiation
of bilaterally symmetrical
animals.42 In other words,
the common ancestor of flies and frogs was also the common ancestor of
mammals, reptiles, echinoderms, mollusks, and nematodes. Moreover, the
nematode Caenorhabditis elegans
has 2 Notch genes (also known
as lin-12 and
glp-1), which are more diverged
than any pair of mammalian
Notch genes. In fact,
lin-12 and
glp-1 share only
50% amino
acid identity with each other, they are expressed in different tissues,
and they have different numbers of EGF repeats. Nevertheless,
lin-12 and
glp-1 have proven to be
biochemically interchangeable in the sense that they activate
the same signal transduction
pathway,43 and each can
substitute for the other if expressed in the appropriate
tissues.44 Taken together,
the available evidence suggests that the basic structure and molecular
functions of the Notch receptor have probably been conserved since
before the origin of vertebrates.
 |
Does CADASIL Result From a Notch Signaling
Defect or a Protein Accumulation Problem?
|
|---|
None of the >50 CADASIL alleles sequenced to date
appear
to represent a null allele (such as a frameshift or
deletion)
of
NOTCH3. This led
Spinner
45 to suggest that
CADASIL may not
arise from a loss of Notch signaling. However,
extensive studies
of Notch in flies, worms, frogs, and mice have shown
that cells
that synthesize the Notch receptor respond to Notch
signaling
with dramatic changes in proliferation, differentiation, or
developmental
fate switching, whereas cells that become refractory to
the
Notch pathway invariably stop synthesizing the Notch
receptor.
21 23 32 39 40 46 47 48
These rules hold even for
Notch1 expression
in
postmitotic neurons in the mammalian
brain.
49 50
Because
adult human vascular smooth muscle cells express
NOTCH3 (see
above), it follows
that NOTCH3 signaling is likely to play a
role in vascular smooth
muscle cell proliferation and/or differentiation.
Because cysteine
substitutions in the EGF repeat domain of Notch
are known to have a
profound (dominant inhibitory) effect on
Notch signaling in
Drosophila (see above) and
because the basic
structure and molecular functions of Notch have been
highly
conserved (see above), it follows that cysteine substitutions
in
the EGF repeat domain of human NOTCH3 probably also have
a profound
(dominant inhibitory) effect on NOTCH3 signaling
in
patients with CADASIL. In other words, the comparison with
Drosophila lethal-Abruptex
argues strongly against Spinners first
suggestion (that CADASIL is
caused by protein accumulation,
not loss of Notch signaling) but argues
just as strongly in
favor of Spinners second suggestion (that CADASIL
is
caused by a dominant inhibition of Notch
signaling
45 ).
According to this view, the reason that patients with
CADASIL with null alleles of
NOTCH3 have not been found is
that null alleles cause different symptoms, which are less severe
in heterozygotes (ie, less severe than antimorphs) and are lethal in
homozygotes. This is the same reason that null alleles of
Drosophila Notch do not produce
the lethal-Abruptex
phenotype.30
Moreover, there is ample precedent for our suggestion that a homozygous
null allele of NOTCH3 would
be lethal in humans, given that some
Notch3 mutations in the mouse
are embryonic
lethals.33
 |
Antimorphic Actions of CADASIL and
Lethal-Abruptex Are Probably Related to Formation of Notch
Heterodimers
|
|---|
The Notch receptor exists on the cell surface as a
heterodimer.
This was originally inferred from classical genetic
experiments
with
Drosophila
Abruptex
alleles
25 51
and was later confirmed
by biochemical studies in
insect
32 52 and
mammalian cells.
53
Presumably, this explains why the
Drosophila lethal-Abruptex
gene
product can partially block the function of the normal
gene
product: They interact physically with each other at the
cell
surface.
The extracellular domain of the Notch protein is
constitutively cleaved during processing of the Notch protein in the
Golgi apparatus. The cleavage site is located between the
LIN-12 repeats (named after the nematode
Notch gene in which they were
discovered) and the transmembrane
domain.20 53 The
freed extracellular domain then binds to the remainder of the receptor
(which includes the intracellular domain, the transmembrane segment,
and a small extracellular peptide), forming a
heterodimer.53 The remaining
extracellular peptide must contain the heterodimer binding site, which
is likely to be compact because there are few conserved sequences
within the remaining extracellular peptide (Dr Fryxell, unpublished
observations). Binding of this peptide to the extracellular domain
could easily be disrupted by inappropriate pairing of cysteines within
the EGF repeat domain. Consistent with this view, recent
studies have shown that the extracellular domain of NOTCH3 in patients
with CADASIL fails to bind to the remainder of NOTCH3, is not recycled
by reuptake into the cell as it normally
is,23 and consequently
accumulates to high levels within the extracellular space near vascular
smooth muscle
cells.20
Notch receptors, in general, are stimulated by binding to
transmembrane proteins expressed by neighboring cells (such as Delta,
Serrate, Jagged1, Jagged2, Delta-like1, Delta-like3, and so
on).22 23 32 45
This implies a mechanism by which the release (and consequent
accumulation) of the extracellular domain of NOTCH3 would produce
dominant inhibition of NOTCH3 signalingby competitive inhibition of
binding to its protein
ligand.45 In conclusion, the
comparison of Drosophila
lethal-Abruptex with human CADASIL strengthens the case for dominant
inhibition in both cases. In the case of
Drosophila lethal-Abruptex, we
have clear genetic evidence for dominant inhibition. In the case of
human CADASIL, we have a precisely analogous defect at the molecular
level plus clear biochemical evidence of a mechanism by which dominant
inhibition is likely to occur.
 |
Conclusions
|
|---|
In both human CADASIL and
Drosophila lethal-Abruptex,
cysteine
substitutions within the EGF repeats of Notch cause a partial
(antimorphic)
block of function of the normal allele attributable
to a disruption
of the secondary structure of the extracellular domain
of Notch,
which may include disrupted heterodimer formation and
inappropriate
cross-links to other proteins. The genetic dominance of
CADASIL
is likely to result from antimorphic function in heterozygotes,
whereas
homozygotes probably never will be found because of recessive
lethality.
The cell-autonomous phenotypes of Notch mutations,
together with the histological evidence of cycles of
smooth muscle cell proliferation and degeneration in CADASIL, indicate
that mammalian arterial smooth muscle cells have a
continuing requirement for NOTCH3 activity in the adult. Thus, the
NOTCH3 signaling pathway also may play a role in the response of
arterial smooth muscle cells to other types of injury and
stress.
Finally, the molecular analogy between
Drosophila lethal-Abruptex and
human CADASIL may be of use in the development of potential treatments
for CADASIL. The most obvious approach, namely gene therapy, has
already been tested in flies, and the results are
encouragingadditional copies of the normal
Notch gene do reduce the
symptoms of
lethal-Abruptex.24 54
 |
Acknowledgments
|
|---|
This work was supported by the College of
Arts and Sciences
of George Mason University, through an Indirect Cost
Award and
a Graduate Research Assistantship (both awarded to Dr
Fryxell).
Received September 5, 2000;
revision received November 6, 2000;
accepted November 6, 2000.
 |
References
|
|---|
-
Chabriat
H, Vahedi K, Iba-Zizen MT, Joutel A, Nibbio A, Nagy TG, Krebs MO,
Julien J, Dubois B, Ducrocq X, Levasseur M, Homeyer P, Mas JL,
Lyon-Caen O, Tournier-Lasserve E, Bousser MG. Clinical spectrum of
CADASIL: a study of 7 families.
Lancet. 1995;346:934939.[Medline]
[Order article via Infotrieve]
-
Tournier-Lasserve
E, Iba-Zizen MT, Romero N, Bousser MG. Autosomal dominant syndrome with
strokelike episodes and leukoencephalopathy.
Stroke. 1991;22:12971302.[Abstract/Free Full Text]
-
Verin M, Rolland Y,
Landgraf F, Chabriat H, Bompais B, Michel A, Vahedi K, Martinet JP,
Tournier-Lasserve E, Lemaitre MH, Edan G. New phenotype of the
cerebral autosomal dominant arteriopathy mapped to chromosome 19:
migraine as the prominent clinical feature.
J Neurol Neurosurg Psych. 1995;59:579585.[Abstract]
-
Desmond DW, Moroney
JT, Lynch T, Chan S, Chin SS, Mohr JP. The natural history of CADASIL:
a pooled analysis of previously published cases.
Stroke. 1999;30:12301233.[Abstract/Free Full Text]
-
Davous P. The
natural history of CADASIL.
Stroke. 1999;30:2247.
Abstract.
-
Joutel A, Corpechot
C, Ducros A, Vahedi K, Chabriat H, Mouton P, Alamowitch S, Domenga V,
Cecillion M, Marechal E, Maciazek J, Vayssiere C, Cruaud C, Cabanis E,
Ruchoux M, Weissenbach J, Bach JF, Bousser MG, Tournier-Lasserve E.
Notch3 mutations in CADASIL, a
hereditary adult-onset condition causing stroke and dementia.
Nature. 1996;383:707710.[Medline]
[Order article via Infotrieve]
-
Williamson EE,
Chukwudelunzu FE, Meschia JF, Witte RJ, Dickson DW, Cohen MD.
Distinguishing primary angiitis of the central nervous system from
cerebral autosomal dominant arteriopathy with subcortical infarcts and
leukoencephalopathy: the importance of family history.
Arthritis Rheum. 1999;42:22432248.[Medline]
[Order article via Infotrieve]
-
Baudrimont M, Dubas
F, Joutel A, Tournier-Lasserve E, Bousser MG. Autosomal dominant
leukoencephalopathy and subcortical ischemic stroke: a
clinicopathological study.
Stroke. 1993;24:122125.[Abstract/Free Full Text]
-
Ruchoux MM,
Chabriat H, Bousser MG, Baudrimont M, Tournier-Lasserve E. Presence of
ultrastructural arterial lesions in muscle and skin vessels
of patients with CADASIL.
Stroke. 1994;25:22912292.[Medline]
[Order article via Infotrieve]
-
Schröder JM,
Sellhaus B, Jörg J. Identification of the characteristic vascular
changes in a sural nerve biopsy of a case with cerebral autosomal
dominant arteriopathy with subcortical infarcts and leukoencephalopathy
(CADASIL). Acta Neuropathol. 1995;89:116121.[Medline]
[Order article via Infotrieve]
-
Malandrini A,
Carrera P, Palmeri S, Cavallaro T, Fabrizi GM, Villanova M, Fattapposta
M, Vismara L, Brancolini V, Tanganelli P, Calí A, Morocutti C,
Zeviani M, Ferrari M, Guazzi GC. Clinicopathological and genetic
studies of two further Italian families with cerebral autosomal
dominant arteriopathy. Acta
Neuropathol. 1996;92:115122.[Medline]
[Order article via Infotrieve]
-
Ruchoux M-M,
Guerouaou D, Vandenhaute B, Pruvo J-P, Vermersch P, Leys D. Systemic
vascular smooth muscle impairment in cerebral autosomal dominant
arteriopathy with subcortical infarcts and leukoencephalopathy.
Acta Neuropathol. 1995;89:500512.[Medline]
[Order article via Infotrieve]
-
Chabriat H,
Pappata S, Poupon C, Clark CA, Vahedi K, Poupon F, Mangin JF,
Pachot-Clouard M, Jobert A, Le Bihan D, Bousser M-G. Clinical severity
in CADASIL related to ultrastructural damage in white matter: in vivo
study with diffusion tensor MRI.
Stroke. 1999;30:26372643.[Abstract/Free Full Text]
-
Tournier-Lasserve
E, Joutel A, Melki J, Weissenbach J, Lathrop GM, Chabriat H, Mas JL,
Cabanis EA, Baudrimont M, Maciazek J. Cerebral autosomal dominant
arteriopathy with subcortical infarcts and leukoencephalopathy maps to
chromosome 19q12. Nat Genet. 1993;3:256259.[Medline]
[Order article via Infotrieve]
-
Ducros A, Nagy T,
Alamowitch S, Nibbio A, Joutel A, Vahedi K, Chabriat H, Iba-Zizen MT,
Julien J, Davous P, Goas JY, Lyon-Caen O, Dubois B, Ducrocq X, Salsa F,
Ragno M, Burkhard P, Bassetti C, Hutchinson M, Verin M, Viader F,
Chapon F, Levasseur M, Mas JL, Delrieu O, Maciazek J, Prieur M,
Mohrenweiser H, Bach JF, Bousser MG, Tournier-Lasserve E. Cerebral
autosomal dominant arteriopathy with subcortical infarcts and
leukoencephalopathy, genetic homogeneity, and mapping of the locus
within a 2-cM interval. Am J Hum
Genet. 1996;58:171181.[Medline]
[Order article via Infotrieve]
-
Joutel A, Vahedi
K, Corpechot C, Troesch A, Chabriat H, Vayssiere C, Cruad C, Maciazek
J, Weissenbach J, Bousser M-G, Bach J-F, Tournier-Lasserve E. Strong
clustering and stereotyped nature of
Notch3 mutations in CADASIL
patients. Lancet. 1997;350:15111515.[Medline]
[Order article via Infotrieve]
-
Kamimura K,
Takahashi K, Uyama E, Tokunaga M, Kotorii S, Uchino M, Tabira T.
Identification of a Notch3
mutation in Japanese CADASIL family: cerebral autosomal dominant
arteriopathy with subcortical infarcts and leukoencephalopathy.
Alzheimer Dis Assoc
Disord. 1999;13:222225.[Medline]
[Order article via Infotrieve]
-
Ceroni M, Poloni
TE, Tonietti S, Fabozzi D, Uggetti C, Frediani F, Simonetti F,
Malaspina A, Alimonti D, Celano M, Ferrari M, Carrera P. Migraine with
aura and white matter abnormalities:
Notch3 mutation.
Neurology. 2000;54:18691871.[Abstract/Free Full Text]
-
Joutel A,
Chabriat H, Vahedi K, Domenga V, Vayssiere C, Ruchoux MM, Lucas C, Leys
D, Bousser MG, Tournier-Lasserve E. Splice site mutation causing a
seven amino acid Notch3
in-frame deletion in CADASIL.
Neurology. 2000;54:18741875.[Free Full Text]
-
Joutel A, Andreux
F, Gaulis S, Domenga V, Cecillon M, Battail N, Piga N, Chapon F,
Godfrain C, Tournier-Lasserve E. The ectodomain of the Notch3 receptor
accumulates within the cerebrovasculature of CADASIL patients.
J Clin Invest. 2000;105:597605.[Medline]
[Order article via Infotrieve]
-
Fryxell KJ,
Miller TA. Autocidal biological control: a general strategy for insect
control based on genetic transformation with a highly conserved gene.
J Econ Entomol. 1995;88:12211232.
-
Greenwald I,
Rubin GM. Making a difference: the role of cell-cell interactions in
establishing separate identities for equivalent cells.
Cell. 1992;68:271281.[Medline]
[Order article via Infotrieve]
-
Kimble J, Simpson
P. The LIN-12/Notch signaling
pathway and its regulation. Annu Rev Cell
Dev Biol. 1997;13:333361.[Medline]
[Order article via Infotrieve]
-
Portin P. The
antimorphic mode of action of lethal Abruptex alleles of the
Notch locus in
Drosophila melanogaster.
Hereditas. 1981;95:247251.
-
Portin P. Allelic
negative complementation at the
Abruptex locus of
Drosophila melanogaster.
Genetics. 1975;81:121133.[Abstract/Free Full Text]
-
de Celis JF,
Garcia-Bellido A. Modifications of the Notch function by
Abruptex mutations in
Drosophila melanogaster.
Genetics. 1994;136:183194.[Abstract]
-
Lieber T, Wesley
CS, Alcamo E, Hassel B, Krane JF, Campos-Ortega JA, Young MW. Single
amino acid substitutions in EGF-like elements of Notch and Delta modify
Drosophila development and
affect cell adhesion in vitro.Neuron. 1992;9:847859.[Medline]
[Order article via Infotrieve]
-
Kelley MR, Kidd
S, Deutsch WA, Young MW. Mutations altering the structure of epidermal
growth factor-like coding sequences at the Drosophila
Notch locus.
Cell. 1987;51:539548.[Medline]
[Order article via Infotrieve]
-
Muller HJ.
Further studies on the nature and causes of gene mutations.
Proc 6th Int Congr Genet. 1932;1:213255.
-
Lindsley DL, Zimm
GG. The Genome of
Drosophila Melanogaster. New
York, NY: Academic Press; 1992.
-
Lawrence PA.
The Making of a Fly: The Genetics of
Animal Design. London, UK: Blackwell Scientific
Publications; 1992.
-
Artavanis-Tsakonas
S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal
integration in development.
Science. 1999;284:770776.[Abstract/Free Full Text]
-
Lardelli M,
Williams R, Mitsiadis T, Lendahl U. Expression of the Notch3
intracellular domain in mouse central nervous system progenitor cells
is lethal and leads to disturbed neural tube development.
Mech Dev. 1996;59:177190.[Medline]
[Order article via Infotrieve]
-
de Celis JF, Mari
Beffa M, Garcia-Bellido A. Cell-autonomous role of
Notch, an epidermal growth
factor homologue in sensory organ differentiation in
Drosophila. Proc Natl Acad Sci
U S A
. 1991;88:632636.
-
Williams R,
Lendahl U, Lardelli M. Complementary and combinatorial patterns of
Notch gene family expression
during early mouse development. Mech
Dev. 1995;53:357368.[Medline]
[Order article via Infotrieve]
-
Lardelli M,
Dahlstrand J, Lendahl U. The novel
Notch homologue mouse
Notch3 lacks specific epidermal
growth factor repeats and is expressed in proliferating
neuroepithelium. Mech Dev. 1994;46:123136.[Medline]
[Order article via Infotrieve]
-
Lindsell CE,
Boulter J, diSibio G, Gossler A, Weinmaster G. Expression patterns of
Jagged1,
Delta1,
Notch1,
Notch2, and
Notch3 genes identify
ligand-receptor pairs that may function in neural development.
Mol Cell Neurosci. 1996;8:1427.[Medline]
[Order article via Infotrieve]
-
Mitsiadis TA, Kaj
F, Christo G. Reactivation of
Delta-Notch signaling after
injury: complementary expression patterns of ligand and receptor in
dental pulp. Exp Cell Res. 1999;246:312318.[Medline]
[Order article via Infotrieve]
-
Coffman CR,
Skoglund P, Harris WA, Kintner CR. Expression of an extracellular
deletion of Xotch diverts cell
fate in Xenopus embryos.
Cell. 1993;73:659671.[Medline]
[Order article via Infotrieve]
-
Kopan R, Nye JS,
Weintraub H. The intracellular domain of mouse
Notch: a constitutively
activated repressor of myogenesis directed at the basic
helix-loop-helix region of MyoD.
Development. 1994;120:23852396.
-
Rebay I, Fleming
RJ, Fehon RG, Cherbas L, Cherbas P, Artavanis-Tsakonas S. Specific EGF
repeats of Notch mediate interactions with Delta and Serrate:
implications for Notch as a multifunctional receptor.
Cell. 1991;67:687699.[Medline]
[Order article via Infotrieve]
-
Knoll AH, Carroll
SB. Early animal evolution: emerging views from comparative biology and
geology. Science. 1999;284:21292137.[Abstract/Free Full Text]
-
Tax FE,
Thomas JH, Ferguson EL, Horvitz HR. Identification and
characterization of genes that interact with
lin-12 in
Caenorhabditis elegans.
Genetics. 1997;147:16751695.[Abstract]
-
Fitzgerald K,
Wilkinson HA, Greenwald I.
glp-1 can substitute for
lin-12 in specifying cell fate
decisions in Caenorhabditis elegans.
Development. 1993;119:10191027.[Abstract]
-
Spinner NB.
CADASIL: Notch signaling defect or protein accumulation problem?
J Clin Invest. 2000;105:561562.[Medline]
[Order article via Infotrieve]
-
Cagan RL, Ready
DF. Notch is required for
successive cell decisions in the developing
Drosophila retina.
Genes Dev. 1989;3:10991112.[Abstract/Free Full Text]
-
Fortini ME,
Artavanis-Tsakonas S. Notch:
neurogenesis is only part of the picture.
Cell. 1993;75:12451247.[Medline]
[Order article via Infotrieve]
-
Kidd S, Baylies
MK, Gasic GP, Young MW. Structure and distribution of the Notch protein
in developing Drosophila. Genes
Dev. 1989;3:11131129.[Abstract/Free Full Text]
-
Nenad S,
Artavanis-Tsakonas S, Rakic P. Contact-dependent inhibition of cortical
neurite growth mediated by Notch signaling.
Science. 1999;286:741746.[Abstract/Free Full Text]
-
Berezovska O,
Mclean P, Knowles R, Frosh M, Lu FM, Lux SE, Hyman BT. Notch1 inhibits
neurite outgrowth in postmitotic primary neurons.
Neuroscience. 1999;93:433439.[Medline]
[Order article via Infotrieve]
-
Foster G.
Negative complementation at the
Notch locus of
Drosophila melanogaster.
Genetics. 1975;81:99120.[Abstract/Free Full Text]
-
Blaumueller CM,
Qi H, Zagouras P, Artavanis-Tsakonas S. Extracellular cleavage of Notch
leads to a heterodimeric receptor on the plasma membrane.
Cell. 1997;90:281291.[Medline]
[Order article via Infotrieve]
-
Logeat F, Bessia
C, Brou C, LeBail O, Jarriault S, Seidah NG, Israel A. The Notch1
receptor is cleaved constitutively by a furin-like convertase.
Proc Natl Acad Sci
U S A
. 1998;95:81088112.
-
Sirén M, Portin
P. Gene dosage studies of a temperature sensitive
Abruptex mutation of the
Notch locus of
Drosophila melanogaster.
Hereditas. 1989;110:175178.
Editorial Comment
Joseph M. Verdi, PhD, Guest Editor
Christopher J. Kubu, MSc, Guest Editor
Laboratory
of Neural Stem Cell Biology,
Robarts Research Institute,
Department of Physiology, Program in
Neuroscience,
London, Ontario,
Canada
 |
Introduction
|
|---|
The Notch-mediated signaling pathway is
evolutionarily conserved
and controls cell fate determination and
differentiation in
several
Drosophila and mammalian
lineages. Both
Drosophila and
mammalian
Notch are transmembrane receptor proteins for Delta and
Delta-like
ligands. To date, 4 distinct mammalian Notch genes have been
identified
in mammals. On activation by its ligand (Delta or Jagged),
the
intracellular domain of Notch is cleaved and transports the
Suppressor
of Hairless transcription factor (CBF1 in mammals) into the
nucleus
and acts as a transactivator for Enhancer of Split
(HES in mammals)
gene expression. Notch activation thus acts as a
transducer
of extrinsic signals into altered gene
expression.
The role of Notch signaling in human disease is receiving
great attention of late with the finding that presenilins, genes
associated with early onset familial Alzheimers disease, are
regulators of Notch
signaling.R1 This has led to
the theoretical possibility that Notch signaling may underlie the cause
of this autosomal dominant variant of the disease. Whereas this
hypothesis is founded on strictly correlative data, alterations in
Notch signaling are at the core of 2 autosomal dominant disorders
called Alagille syndrome (Jagged
mutantR2 ) and cerebral
autosomal dominant arteriopathy with subcortical infarcts and
leukoencephalopathy
(CADASILR3 ; see also
references within the preceding [Fryxell] article).
Alagille syndrome is characterized by bile duct paucity and
resultant liver disease in combination with cardiac, skeletal, ocular,
and facial abnormalities. CADASIL results from mutations within the
extracellular domain of the Notch 3 receptor that disrupt the normal
cysteine patterning required for proper ligand binding and receptor
activation. CADASIL is associated with a wide spectrum of symptomology,
including migraines, mood disorders, epileptic seizures, progressive
dementia, and stroke. The question in developmental biology and
clinical science is how can we lean more about the roles Notch
signaling plays in these disorders and how can we use this knowledge to
develop new treatment regimes to treat human patients.
In a brilliantly written article, Dr Karl Fryxell and his
research team make the strong case for using animal models of disease
to elucidate potential targets for gene therapy or pharmaceutical
intervention. The authors compare and contrast the effects of
extracellular mutations in Notch in
Drosophila (only one Notch
species in Drosophila) and
Notch 3 in mice to the human equivalent that results in CADASIL. The
molecular and morphological correlates of extracellular Notch mutations
in Drosophila and Notch 3
mutations in mice match the clinical consequences of CADASIL in human
populations. What is particularly insightful about this article is that
the authors take this correlative data and make a strong case for using
the power of Drosophila
genetics to gain insight into human disease. Specifically, the author
suggests (and rightly so) that weak alleles of Notch (called
AbruptexR4 )
in Drosophila will serve as
good models for studying CADASIL in humans and provide a viable model
for testing gene replacement therapies to rescue the mutant
phenotype. Also, genetic alterations to Notch 3 signaling in
mice either by knock-out or transgenic technology will also be valued
tools in learning more about this disease in particular and about
smooth muscle development in general. The attempt by Fryxell et al to
find new ways of integrating what is learned in these genetic
experiments into the clinic to treat human suffering should be
complimented, and studies in this vein should render both interesting
and clinically relevant results. In particular, their idea of using
wild-type Notch and components of the Notch signaling pathway as
potential candidates for gene therapy is right on the mark. Taking this
idea a step further, using the power of
Drosophila genetics to identify
other targets for either conventional pharmaceutical intervention or
gene therapy would warrant consideration. One classic way to identify
genes involved in a particular developmental pathway is called
suppressor or enhancer screens. In
Drosophila, this consists of
taking individual fly lines, each with a random mutation within its
genome, and breeding these flies with a weak
Abruptex phenotype to
determine whether mutation X exacerbates the
Abruptex phenotype,
rescues the phenotype, or does nothing. Those mutations that
alter the Abruptex
phenotype can be easily cloned and represent potential
new targets for drug design or gene therapy. These powerful techniques,
as pointed out by Fryxell and colleagues, are possible only in
Drosophila with the speed and
efficacy required.
Recently, Notch 3 has been shown to act more as a repressor
of HES function than an
activator.R5 The
conclusions drawn from the study of Fryxell and colleagues are enhanced
by these observations. An increase in Notch extracellular domain may in
fact sequester the available ligand required for normal signaling,
making CADASIL still a dominant autosomal mutation, but gene therapy
regimes and future experiments need to examine the actual regulation of
HES in these studies. The authors point out that overexpression of
normal Notch in Abruptex
mutants rescues the
phenotype.R4 It is
conceivable that Abruptex and
Notch 3 mutants in mice may be rescued by restoration of Enhancer of
Split (HES in mammals) levels and, ultimately, any of the downstream
regulators identified in suppresser or enhancer of
Abruptex genetic screens. If
true, this opens the range of potential therapeutic targets for
treatment of CADASIL.
It must be somewhat frustrating for
Drosophila geneticists at times
to have their organism referred to as "simple," given all the
complex questions one can address by using this model. That,
unfortunately, is still exactly the case anytime someone working on
Drosophila, C elegans, and
zebrafish genetics or development is introduced at seminars. The notion
that these systems are simple is even scattered throughout textbooks
concerning the subject. As more articles like the insightful and
challenging one presented by Fryxell and colleagues appear, the
bias or label should be erased. "Simple systems," indeed. Kudos, Dr
Fryxell.
Received September 5, 2000;
revision received November 6, 2000;
accepted November 6, 2000.
 |
References
|
|---|
-
Chan Y-M,
Jan YN. Presenilins, processing of ß-amyloid precursor protein, and
Notch signaling. Cell. 1999;23:201204.
-
Jones EA,
Clement-Jones M, Wilson DI. Jagged1 expression in human embryos:
correlation with the Alagille syndrome phenotype.
J Med Genet. 2000;37:663668.[Abstract/Free Full Text]
-
Joutel A, Andreux
F, Gaulis S, Domenga V, Cecillon M, Battail N, Piga N, Chapon F,
Godfrain C, Tournier-Lasserve E. The ectodomain of
Notch3 receptor accumulates
within the cerebrovasculature of CADASIL patients.
J Clin Invest. 2000;105:597605.
-
Siren M, Portin P.
Gene dosage studies of temperature sensitive
Abruptex mutation of the
Notch locus of
Drosophila melanogaster.
Hereditas. 1998;110:175178.
-
Beatus P,
Lundkvist J, Oberg C, Lendahl U. The Notch 3 intracellular domain
represses Notch 1-mediated activation through Hairy/Enhancer of Split
promoters. Development. 1999;126:39153935.[Abstract]
This article has been cited by other articles:

|
 |

|
 |
 
M. M. Ruchoux, V. Domenga, P. Brulin, J. Maciazek, S. Limol, E. Tournier-Lasserve, and A. Joutel
Transgenic Mice Expressing Mutant Notch3 Develop Vascular Alterations Characteristic of Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy
Am. J. Pathol.,
January 1, 2003;
162(1):
329 - 342.
[Abstract]
[Full Text]
[PDF]
|
 |
|